A COMPARISON OF EPSTEIN-BARR VIRUS-SPECIFIC T-CELL IMMUNITY IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS PATIENTS

1983 ◽  
Vol 61 (5) ◽  
pp. 509-516 ◽  
Author(s):  
DJ Moss ◽  
A Klestov ◽  
S Burrows ◽  
RG Kane
Keyword(s):  
Rheumatoid Arthritis ◽  
T Cell ◽  
Epstein Barr Virus ◽  
T Cell Immunity ◽  
Barr Virus ◽  
Cell Immunity ◽  
Epstein Barr

scholarly journals Epstein-Barr Virus Isolates Retain Their Capacity To Evade T Cell Immunity through BNLF2a despite Extensive Sequence Variation

2011 ◽  
Vol 86 (1) ◽  
pp. 572-577 ◽  
Author(s):  
D. Horst ◽  
S. R. Burrows ◽  
D. Gatherer ◽  
B. van Wilgenburg ◽  
M. J. Bell ◽  
...  
Keyword(s):  
T Cell ◽  
Epstein Barr Virus ◽  
Sequence Variation ◽  
T Cell Immunity ◽  
Extensive Sequence ◽  
Barr Virus ◽  
Cell Immunity ◽  
Epstein Barr ◽  
Virus Isolates

A comparison of epstein-barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea

1983 ◽  
Vol 31 (6) ◽  
pp. 727-732 ◽  
Author(s):  
D. J. Moss ◽  
S. R. Burrows ◽  
D. J. Castelino ◽  
R. G. Kane ◽  
J. H. Pope ◽  
...  
Keyword(s):  
T Cell ◽  
Papua New Guinea ◽  
Epstein Barr Virus ◽  
New Guinea ◽  
T Cell Immunity ◽  
Barr Virus ◽  
Cell Immunity ◽  
Epstein Barr

scholarly journals Epstein?Barr virus T-cell immunity despite rituximab

2007 ◽  
Vol 136 (4) ◽  
pp. 628-632 ◽  
Author(s):  
Angela K. Nehring ◽  
Ujjwal Dua ◽  
Peter Mollee ◽  
Devinder Gill ◽  
Karen Grimmett ◽  
...  
Keyword(s):  
T Cell ◽  
Epstein Barr Virus ◽  
T Cell Immunity ◽  
Barr Virus ◽  
Cell Immunity ◽  
Epstein Barr

Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products

2008 ◽  
Vol 18 (6) ◽  
pp. 397-408 ◽  
Author(s):  
Maaike E. Ressing ◽  
Daniëlle Horst ◽  
Bryan D. Griffin ◽  
Judy Tellam ◽  
Jianmin Zuo ◽  
...  
Keyword(s):  
T Cell ◽  
Epstein Barr Virus ◽  
T Cell Immunity ◽  
Cd4 T Cell ◽  
Gene Products ◽  
Multiple Gene ◽  
Barr Virus ◽  
Cell Immunity ◽  
Epstein Barr

scholarly journals Epstein–Barr virus strain heterogeneity impairs human T-cell immunity

2018 ◽  
Vol 67 (4) ◽  
pp. 663-674 ◽  
Author(s):  
Ana Cirac ◽  
Simon Stützle ◽  
Michael Dieckmeyer ◽  
Dinesh Adhikary ◽  
Andreas Moosmann ◽  
...  
Keyword(s):  
T Cell ◽  
Virus Strain ◽  
Epstein Barr Virus ◽  
T Cell Immunity ◽  
Barr Virus ◽  
Human T Cell ◽  
Cell Immunity ◽  
Epstein Barr

scholarly journals Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma

2020 ◽  
Vol 21 (12) ◽  
pp. 4292 ◽  
Author(s):  
Sarah Renaud ◽  
Anthony Lefebvre ◽  
Serge Mordon ◽  
Olivier Moralès ◽  
Nadira Delhem
Keyword(s):  
T Cell ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
T Cell Immunity ◽  
Epithelial Tissue ◽  
High Morbidity ◽  
Barr Virus ◽  
High Morbidity Rate ◽  
Cell Immunity ◽  
Epstein Barr

Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75–95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy’s being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease’s aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity.

scholarly journals Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein–Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth

Vaccines ◽  
2019 ◽  
Vol 7 (2) ◽  
pp. 44 ◽  
Author(s):  
Krzysztof Wojtak ◽  
Alfredo Perales-Puchalt ◽  
David B. Weiner
Keyword(s):  
T Cell ◽  
Tumor Growth ◽  
Epstein Barr Virus ◽  
Tumor Antigens ◽  
Adult Population ◽  
T Cell Immunity ◽  
Nuclear Antigen ◽  
Barr Virus ◽  
Cell Immunity ◽  
Epstein Barr

Infectious diseases are linked to 15%–20% of cancers worldwide. Among them, Epstein–Barr virus (EBV) is an oncogenic herpesvirus that chronically infects over 90% of the adult population, with over 200,000 cases of cancer and 150,000 cancer-related deaths attributed to it yearly. Acute EBV infection can present as infectious mononucleosis, and lead to the future onset of multiple cancers, including Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric carcinoma. Many of these cancers express latent viral genes, including Epstein–Barr virus nuclear antigen 1 (EBNA1) and latent membrane proteins 1 and 2 (LMP1 and LMP2). Previous attempts to create potent immunogens against EBV have been reported but generated mixed success. We designed novel Synthetic Consensus (SynCon) DNA vaccines against EBNA1, LMP1 and LMP2 to improve on the immune potency targeting important antigens expressed in latently infected cells. These EBV tumor antigens are hypothesized to be useful targets for potential immunotherapy of EBV-driven cancers. We optimized the genetic sequences for these three antigens, studied them for expression, and examined their immune profiles in vivo. We observed that these immunogens generated unique profiles based on which antigen was delivered as the vaccine target. EBNA1vax and LMP2Avax generated the most robust T cell immunity. Interestingly, LMP1vax was a very weak immunogen, generating very low levels of CD8 T cell immunity both as a standalone vaccine and as part of a trivalent vaccine cocktail. LMP2Avax was able to drive immunity that impacted EBV-antigen-positive tumor growth. These studies suggest that engineered EBV latent protein vaccines deserve additional study as potential agents for immunotherapy of EBV-driven cancers.

Sign in / Sign up

Export Citation Format

Share Document